Sign In
Buy LXRX
$2.31
-0.0300 (-1.28%)
At Close: Jul 31, 2026
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
04:05pm, Thursday, 02'nd May 2024
Commercial launch of INPEFA ® (sotagliflozin) for Heart Failure continues to progress
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
09:00am, Monday, 29'th Apr 2024
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats has provided notice of his retirement as chief executive offic
Lexicon Pharmaceuticals to Host 2024 Investor Day
08:00am, Thursday, 18'th Apr 2024
Includes Business and Scientific Updates from Lexicon Executives and Leading Medical Experts in Hypertrophic Cardiomyopathy, Type 1 Diabetes and Diabetic Peripheral Neuropathic Pain Includes Business
All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
01:01pm, Tuesday, 16'th Apr 2024
Lexicon (LXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
01:46pm, Wednesday, 13'th Mar 2024
New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
09:26am, Monday, 11'th Mar 2024
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.16 per share a year ago.
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
07:15am, Monday, 11'th Mar 2024
Commercial launch of INPEFA ® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
07:05am, Monday, 11'th Mar 2024
THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced it has entered into a securities purchase agreement (the “purc
Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for
11:01am, Thursday, 29'th Feb 2024
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do
10:31am, Friday, 26'th Jan 2024
Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers. Multiple studies support the cost efficacy of Inpefa for
Lexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalization Data May Unlock Significant Value
01:03pm, Thursday, 04'th Jan 2024
LXRX is ~60% of its May highs, despite holding an FDA-approved key drug, Inpefa, in its portfolio. The sell-off can be largely attributed to concerns over Inpefa's market uptake amid a perfect storm o
3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street
05:06am, Tuesday, 26'th Dec 2023
Growth stocks were responsible for powering the major stock indexes higher in 2023. The prospect of interest rate cuts by the nation's central bank has Wall Street collectively bullish on growth stock
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
04:15pm, Thursday, 21'st Dec 2023
THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place Ja
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
07:30am, Thursday, 30'th Nov 2023
The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain
